Trial Profile
A Phase I Open Label Dose Escalation Study of Continuous (Except on the Days of Chemotherapy Infusion) Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record